Abstract
This research evaluates the efficacy of Astaxanthin (AX) on cerebral ischemia/reperfusion (I/R) injury in rats and elucidates the potential mechanism of its neuronal protective effect. Using a middle cerebral artery occlusion/reperfusion (MCAO/R) model and lipopolysaccharide (LPS)-stimulated rat microglia (RM), the study found that AX inhibits microglial activation and enhances PPAR-γ expression in a dose-dependent manner. The results demonstrate that AX alleviates infarct volume and improves functional recovery by regulating the PPAR-γ/NF-κB signaling pathway.
Introduction
Ischemic stroke remains a leading cause of global mortality and long-term disability. While reperfusion is necessary to save brain tissue, it often triggers a secondary wave of damage known as ischemia/reperfusion (I/R) injury. A central player in this process is the over-activation of microglia, the brain's resident immune cells. When activated, microglia release pro-inflammatory cytokines (such as IL-1β, IL-6, and TNF-α) that exacerbate neuronal death. This study investigates whether Astaxanthin, a natural carotenoid with potent antioxidant properties, can mitigate this inflammatory response by targeting the PPAR-γ/NF-κB axis.
Methods
The study utilized both in vivo and in vitro models:
- Animal Model: Sprague-Dawley rats underwent MCAO/R to simulate stroke. Treatment groups received AX (10 mg/kg), while mechanism-validation groups received PPAR-γ siRNA or the antagonist GW9662.
- Cellular Model: Rat Microglia (RM) were stimulated with LPS to induce an inflammatory state and then treated with AX at concentrations of 1, 5, or 10 μg/mL.
- Evaluations: Researchers measured neurological scores (mNSS), cerebral infarct volume, and the expression of inflammatory markers (CD68, iNOS, CD206) and signaling proteins (PPAR-γ, p-P65) via RT-qPCR and Western Blotting.
Results
Astaxanthin demonstrated significant neuroprotective effects across both models. In rats, AX treatment reduced brain infarct volume and improved sensorimotor and cognitive performance.
In the cellular model, AX treatment suppressed the expression of pro-inflammatory markers while promoting the anti-inflammatory marker CD206. Crucially, AX increased the expression of PPAR-γ protein in a dose-dependent manner. As shown in the data below, increasing concentrations of AX led to a significant reduction in the secretion of inflammatory cytokines like IL-6 and TNF-α, while simultaneously boosting PPAR-γ levels.
The study further confirmed that the protective effects of AX were neutralized when PPAR-γ was silenced or inhibited, proving that AX works specifically through the PPAR-γ/NF-κB pathway to suppress the "master switch" of inflammation.
Discussion
The findings highlight the PPAR-γ/NF-κB axis as a critical therapeutic target for stroke. By activating PPAR-γ, AX prevents the phosphorylation of P65, thereby inhibiting the NF-κB pathway and reducing the inflammatory storm.
While the results are promising, the study notes limitations: AX was administered as a pre-treatment, which may not reflect emergency clinical scenarios where treatment begins post-stroke. Additionally, while the MCAO/R model is a standard, further research is needed to translate these rodent-based findings into human clinical applications. Future work should also explore AX's potential multi-target effects, including its anti-apoptotic and direct antioxidant properties.
Conclusion
Astaxanthin effectively alleviates LPS-induced microglial injury and provides significant protection against cerebral I/R injury in rats. This neuroprotective effect is primarily mediated by the regulation of the PPAR-γ/NF-κB pathway, suggesting that AX could be a viable therapeutic candidate for mitigating the damage caused by ischemic stroke.
Summary updated